Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 8246 participants.

Also called NCT01986881

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 8,246 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01986881
  • EudraCT 2013-002518-11
Other papers using this trial's data
  • Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial The lancet. Healthy longevity, 2023-04 DOI, PubMed 37003273
  • Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes The New England journal of medicine, 2020-10-08 DOI, PubMed 32966714
  • Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial Diabetologia, 2021-06 DOI, PubMed 33665685, PMC8099851 In the PMC Open Access subset under CC BY.
  • Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy Diabetes, obesity & metabolism, 2021-07 DOI, PubMed 33769675, PMC8252001 In the PMC Open Access subset under CC BY-NC-ND.
  • Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial Circulation, 2020-12-08 DOI, PubMed 33026243, PMC7717477 In the PMC Open Access subset under CC BY-NC-ND.
  • Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial Clinical journal of the American Society of Nephrology : CJASN, 2021-09 DOI, PubMed 34497110, PMC8729577 Not in the PMC Open Access subset.
  • Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial Sleep & breathing = Schlaf & Atmung, 2023-05 DOI, PubMed 35596030, PMC10212814 In the PMC Open Access subset under CC BY.
  • Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial BMJ open diabetes research & care, 2021-10 DOI, PubMed 34620621, PMC8499340 In the PMC Open Access subset under CC BY-NC.
  • Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus Diabetes, obesity & metabolism, 2022-09 DOI, PubMed 35603908, PMC9357198 In the PMC Open Access subset under CC BY-NC-ND.
  • The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV Diabetes, obesity & metabolism, 2022-06 DOI, PubMed 35233908

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01986881. Randomized; double masking; primary purpose treatment. Start 2013-11-04 (actual); primary completion 2019-12-27 (actual). Results posted on 2021-02-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ertugliflozin
Intervention (Drug)
Placebo
Intervention (Drug)
Glycemic Rescue
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01986881
Content hash
c43bef21540a5d092343982a4d684634d4fad01e4b8d5c7a9d86033a484b1676